What's Happening?
Bristol Myers Squibb (BMS) has announced the expansion of its 'Standing in the Gaap' program, aimed at addressing care gaps for multiple myeloma patients in underserved communities. The program, marking its tenth year, will now include a comprehensive
survey to better understand challenges in multiple myeloma care. The survey will engage over 1,000 patients, caregivers, and healthcare providers, with input from leading patient advocacy organizations. The initiative seeks to improve equitable access to education, resources, and community-driven solutions for multiple myeloma care.
Why It's Important?
The expansion of the 'Standing in the Gaap' program highlights BMS's commitment to addressing healthcare disparities. By focusing on underserved communities, the program aims to improve access to care and support for multiple myeloma patients. The survey will provide valuable insights into the real-world challenges faced by patients and caregivers, informing future strategies and interventions. This initiative reflects a broader industry trend towards patient-centered care and the importance of addressing social determinants of health.
What's Next?
Bristol Myers Squibb will analyze the survey results to identify areas where support is lacking and develop targeted interventions. The company plans to share findings with stakeholders and use them to guide future programming and partnerships. Continued collaboration with patient advocacy organizations will be crucial in ensuring the program's success and impact. The initiative may also influence broader healthcare policies and practices related to multiple myeloma care.
